Immunitybio Stock Probability of Future Stock Price Finishing Under 0.26
| IBRX Stock | USD 5.12 0.08 1.59% |
Immunitybio |
Immunitybio Target Price Odds to finish below 0.26
The tendency of Immunitybio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.26 or more in 90 days |
| 5.12 | 90 days | 0.26 | near 1 |
Based on a normal probability distribution, the odds of Immunitybio to drop to $ 0.26 or more in 90 days from now is near 1 (This Immunitybio probability density function shows the probability of Immunitybio Stock to fall within a particular range of prices over 90 days) . Probability of Immunitybio price to stay between $ 0.26 and its current price of $5.12 at the end of the 90-day period is about 87.94 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.25 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Immunitybio will likely underperform. Additionally Immunitybio has an alpha of 0.2956, implying that it can generate a 0.3 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Immunitybio Price Density |
| Price |
Predictive Modules for Immunitybio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immunitybio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Immunitybio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Immunitybio is not an exception. The market had few large corrections towards the Immunitybio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Immunitybio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Immunitybio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.30 | |
β | Beta against Dow Jones | 1.25 | |
σ | Overall volatility | 0.81 | |
Ir | Information ratio | 0.05 |
Immunitybio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immunitybio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immunitybio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Immunitybio is way too risky over 90 days horizon | |
| Immunitybio appears to be risky and price may revert if volatility continues | |
| Immunitybio has high likelihood to experience some financial distress in the next 2 years | |
| Immunitybio currently holds 726.72 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 622 K. Net Loss for the year was (583.2 M) with profit before overhead, payroll, taxes, and interest of 240 K. | |
| Immunitybio currently holds about 82.94 M in cash with (366.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21. | |
| Immunitybio has a poor financial position based on the latest SEC disclosures | |
| Roughly 77.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: ImmunityBio Completes ANKTIVAs Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71 percent with a Durable Duration of Response Ranging Up to 54 Months |
Immunitybio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Immunitybio Stock often depends not only on the future outlook of the current and potential Immunitybio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immunitybio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 508.6 M | |
| Cash And Short Term Investments | 266.5 M |
Immunitybio Technical Analysis
Immunitybio's future price can be derived by breaking down and analyzing its technical indicators over time. Immunitybio Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Immunitybio. In general, you should focus on analyzing Immunitybio Stock price patterns and their correlations with different microeconomic environments and drivers.
Immunitybio Predictive Forecast Models
Immunitybio's time-series forecasting models is one of many Immunitybio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Immunitybio's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Immunitybio
Checking the ongoing alerts about Immunitybio for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Immunitybio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Immunitybio is way too risky over 90 days horizon | |
| Immunitybio appears to be risky and price may revert if volatility continues | |
| Immunitybio has high likelihood to experience some financial distress in the next 2 years | |
| Immunitybio currently holds 726.72 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 622 K. Net Loss for the year was (583.2 M) with profit before overhead, payroll, taxes, and interest of 240 K. | |
| Immunitybio currently holds about 82.94 M in cash with (366.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21. | |
| Immunitybio has a poor financial position based on the latest SEC disclosures | |
| Roughly 77.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: ImmunityBio Completes ANKTIVAs Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71 percent with a Durable Duration of Response Ranging Up to 54 Months |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.